Menu
The updated ACC/AHA guidelines reflect the growing support for a CT + FFRCT pathway suggesting a revolutionary shift in the diagnosis and management of coronary artery disease is underway. Recognizing the value of coupling CT with the HeartFlow Analysis, Norton Healthcare was an early adopter of a CT-first pathway. In this webinar recording, learn how and why they enacted and implemented this strategy, including lessons learned, current state and benefits, how they leverage different imaging modalities, and what the future holds.
The Society of Cardiovascular Computed Tomography (SCCT) hosted a series of webinars last year reviewing and highlighting the impact of the updated 2021 ACC/AHA Chest Pain Guidelines on clinical practice. Learn about the unique and growing role of the CCTA and FFRCT pathway as the panelists discuss their adoption and program growth strategies and how we can meet today’s clinical challenges with precision technology solutions.
Delivering Precision Patient Care with HeartFlow FFRCT
Panelists:
Maros Ferencik, MD, PhD, Geoffrey Rose, MD, and Charley Taylor, PhD
Update on Management of Acute Chest Pain
Moderated by:
Speakers:
Ron Blankstein, MD, MSCCT & Koon Nieman, MD, PhD, MSCCT
David Morrow, MD, MPH, Maros Ferencik, MD, PhD, MCR, FSCCT, Andrew Choi, MD, FSCCT, Leslee Shaw, PhD, MSCCT, Renee Bullock-Palmer, MD, FSCCT
Update on Management of Stable Chest Pain
Moderated by:
Speakers:
Eric Williamson, MD, MSCCT & Leslee Shaw, PhD, MSCCT
Martha Gulati, MD, MS, Ron Blankstein, MD, MSCCT, Leslee Shaw, PhD, MSCCT, Ajay Kirtane, MD
This TCT symposium demonstrates the positive impact of a CTA + FFRCT pathway, providing practical tips for optimizing use of the HeartFlow Analysis in pre-procedural planning and in the cath lab. You will learn about updates to the new ACC/AHA Chest Pain Guidelines and impact to interventional cardiologists, as well as the value of the CCTA + HeartFlow pathway and how the HeartFlow Analysis can be used in the cath lab. The panelists also review clinical application highlighted with three patient case examples.
Chair:
Faculty:
Campbell Rogers, MD
Leslee J. Shaw, PhD, Jaime Gomez, MD, Umar Rashid, MD, Carlos Collet, MD, PhD
This series of videos features case review-based discussions with some of the world’s leading cardiologists. During this series, learn how leading centers are using FFRCT to help evaluate the impact a blockage may be having on blood flow and determine the optimal course of treatment for each patient. Get insights from high volume centers in implementing a CT + FFRCT pathway, as well as review clinical evidence, supporting clinical utility health economics and safety of the HeartFlow Analysis.
Panelists:
Dr. Jonathon Leipsic, MD, FRCPC, MSCCT, and Dr. Carlos Collet, MD
A discussion on the importance of coronary physiology and the disconnect between anatomy and physiology.
In the middle of a global crisis, leading US physicians discussed the implications of the COVID-19 pandemic at their hospitals, in their departments and on the care they are providing to their cardiac patients.
Moderator:
Panelists:
Dr. Jonathon Leipsic, MD, FRCPC, MSCCT, Providence Health Care
Part I: Drs. Michael Kim and Michael Poon, Northwell Health
Part II: Dr. Frederick Welt, University of Utah School of Medicine
Part III: Dr. Geoffrey Rose, Sanger Heart and Vascular Institute
The information provided by the HeartFlow Analysis is intended to be used in conjunction with the patient’s clinical history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement. The HeartFlow Analysis may not be appropriate for all patients. See indications for use for more information. The HeartFlow Analysis, featuring the FFRCT Analysis, RoadMapTM Analysis, Plaque Analysis, and HeartFlow Planner, has received FDA Clearance in the United States of America. The FFRCT Analysis and HeartFlow Planner are CE Marked in Europe and the United Kingdom and approved in Japan and Canada. The HeartFlow Analysis, featuring FFRCT Analysis, RoadMapTM Analysis, Plaque Analysis, and HeartFlow Planner, is commercially available in the United States. The FFRCT Analysis and HeartFlow Planner are commercially available in the United Kingdom. The FFRCT Analysis is also commercially available in Europe, Japan, and Canada.
© 2024 HeartFlow, Inc. | HeartFlow and the HeartFlow logo are registered trademarks of HeartFlow, Inc. Additionally, RoadMap is claimed as a trademark of HeartFlow, Inc. www.heartflow.com | 331 E Evelyn Ave, Mountain View, CA 94041
*Required fields
If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.
*Required fields
オンライン提出フォームから研究助成金を申請してください。
HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用することを目的としています。
ハートフロー分析に関する追加の適応情報については、次のサイトをご覧ください。www.heartflow.com/indications.
さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.
The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.
For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.
If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.Please use our online submission form on the Clinical Research Page to apply for research grants.
Thank you for your interest!
Executive Vice President and Chief Medical Officer
Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.
He received his A.B. from Harvard College and his M.D. from Harvard Medical School.
本情報は日本国内の医療関係者を対象とした情報提供サイトです。
一般の方に対する情報提供を目的としたものではございません。
あなたは医療関係者ですか？